Duchenne Muscular Dystrophy — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for duchenne muscular dystrophy. 18 active patents protecting 4 drugs from 2+ originators. First major cliff: 2029. Daily refresh.

4
Approved drugs
18
Active US patents
51/100
Avg vulnerability
$1.1B
Annual revenue covered

Originators in Duchenne Muscular Dystrophy

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Sarepta 16 patents Nippon Shinyaku 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating duchenne muscular dystrophy. Each bar = one year. Y-axis scaled to peak year (7 patents).

3
28
3
29
4
30
1
31
7
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Exondys 51
ETEPLIRSEN
 Sarepta 10 63 $300M 2028-10-27
Amondys 45
CASIMERSEN
 Sarepta 5 48 $400M 2029-02-16
Viltepso
VILTOLARSEN
 Nippon Shinyaku 2 36 — 2031-08-31
Vyondys 53
GOLODIRSEN
 Sarepta 1 55 $400M 2028-06-28

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
RE48960 Amondys 45 method of use 83 2029-02-16
RE48468 Exondys 51 method of use 75 2028-10-27
RE48468 Exondys 51 method of use 75 2028-10-27
10781450 Amondys 45 method of use 68 2030-11-12
9758783 Amondys 45 method of use 68 2030-11-12
10870676 Viltepso method of use 68 2031-08-31
10337003 Exondys 51 method of use 62 2034-03-14
9506058 Exondys 51 method of use 62 2034-03-14
10364431 Exondys 51 method of use 62 2034-03-14
10364431 Exondys 51 method of use 62 2034-03-14

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9079934 Viltepso composition of matter 4 2034-04-03
9228187 Amondys 45 composition of matter 10 2030-11-12
10287586 Amondys 45 composition of matter 10 2030-11-12
RE47769 Exondys 51 formulation 55 2029-02-02
RE47769 Exondys 51 formulation 55 2029-02-02
RE47691 Vyondys 53 formulation 55 2028-06-28
9506058 Exondys 51 method of use 62 2034-03-14
10364431 Exondys 51 method of use 62 2034-03-14
10364431 Exondys 51 method of use 62 2034-03-14
10337003 Exondys 51 method of use 62 2034-03-14

Related